Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Feb 28, 2017
SOUTH PLAINFIELD, N.J. , Feb. 28, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2016 financial results and provide an update on the company's business and outlook on Tuesday,
Additional Formats
Feb 21, 2017
SOUTH PLAINFIELD, N.J. , Feb. 21, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on February 20, 2017 it approved non-statutory stock options to purchase an aggregate of 55,900 shares of its common stock to 14 new employees.
Additional Formats
Feb 08, 2017
-Grant Proposals from Nonprofit Patient Advocacy Organizations Due May 31, 2017-
Additional Formats
Jan 09, 2017
SOUTH PLAINFIELD, N.J. , Jan. 9, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) announced that it received notification today from the European Commission (EC) of its adoption of a positive decision granting annual renewal of the conditional marketing authorization for Translarna ™
Additional Formats
Jan 09, 2017
- Preliminary 2016 Translarna unaudited net sales of approximately $81M, a 140% increase vs. 2015 -
- Strategic update for Translarna regulatory path in the U.S. -
- Topline ACT CF data anticipated late first quarter 2017 -
- SMA program actively enrolling patients across SUNFISH and FIREFISH trials -
- RG7916 granted orphan-drug designation for the treatment of SMA -
- Translarna 2017 net sales guidance of $105M to $125M -
Additional Formats
Jan 06, 2017
SOUTH PLAINFIELD, N.J. , Jan. 6, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to RG7916 for the treatment of patients with Spinal Muscular Atrophy (SMA).
Additional Formats
Jan 05, 2017
SOUTH PLAINFIELD, N.J. , Jan. 5, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  ( NASDAQ : PTCT) today announced that on January 3, 2017 it approved non-statutory stock options to purchase 4,000 shares of its common stock to one new employee. The award was made pursuant to the NASDAQ inducement
Additional Formats
Jan 05, 2017
SOUTH PLAINFIELD, N.J. , Jan. 5, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) initiated a clinical study in infants with Type I SMA.
Additional Formats
Jan 03, 2017
SOUTH PLAINFIELD, N.J. , Jan. 3, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the company will present a corporate update at the upcoming 35 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 7:30 am PT .
Additional Formats
Dec 16, 2016
SOUTH PLAINFIELD, N.J. , Dec. 16, 2016 /PRNewswire/ --  PTC Therapeutics, Inc.  ( NASDAQ : PTCT) today announced that on December 14, 2016 it approved non-statutory stock options to purchase an aggregate of 5,600 shares of its common stock to two new employees.
Additional Formats